Patents by Inventor Zelda Wasserman

Zelda Wasserman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-? converting enzyme (TACE)
    Patent number: 7482372
    Abstract: The present application describes novel hydantoin derivatives of formula (I): or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, B, R1, R2, R3, R4, R5, R6, R7, R11, and n are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-? converting enzyme (TACE), aggrecanase, or a combination thereof.
    Type: Grant
    Filed: March 30, 2005
    Date of Patent: January 27, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventors: James E. Sheppeck, Jingwu Duan, Chu-Biao Xue, Zelda Wasserman
  • Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE)
    Publication number: 20050171096
    Abstract: The present application describes novel hydantoin derivatives of formula (I): or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, B, R1, R2, R3, R4, R5, R6, R7, R11, and n are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-? converting enzyme (TACE), aggrecanase, or a combination thereof.
    Type: Application
    Filed: March 30, 2005
    Publication date: August 4, 2005
    Inventors: James Sheppeck, Jingwu Duan, Chu-Biao Xue, Zelda Wasserman
  • Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-? converting enzyme (TACE)
    Patent number: 6906053
    Abstract: The present application describes novel hydantoin derivatives of formula (I): or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, B, R1, R2, R3, R4, R5, R6, R7, R11, and n are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-? converting enzyme (TACE), aggrecanase, or a combination thereof.
    Type: Grant
    Filed: May 12, 2004
    Date of Patent: June 14, 2005
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: James E. Sheppeck, Jingwu Duan, Chu-Biao Xue, Zelda Wasserman
  • Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-? converting enzyme (TACE)
    Patent number: 6890915
    Abstract: The present application describes novel hydantoin derivatives of formula (I): or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, B, R1, R2, R3, R4, R5, R6, R7, R11, and n are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-? converting enzyme (TACE), aggrecanase, or a combination thereof.
    Type: Grant
    Filed: May 23, 2002
    Date of Patent: May 10, 2005
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: James E. Sheppeck, Jingwu Duan, Chu-Biao Xue, Zelda Wasserman
  • Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE)
    Publication number: 20040209874
    Abstract: The present application describes novel hydantoin derivatives of formula (I): 1
    Type: Application
    Filed: May 12, 2004
    Publication date: October 21, 2004
    Inventors: James E. Sheppeck, Jingwu Duan, Chu-Biao Xue, Zelda Wasserman
  • Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE)
    Publication number: 20030130273
    Abstract: The present application describes novel hydantoin derivatives of formula (I): 1
    Type: Application
    Filed: May 23, 2002
    Publication date: July 10, 2003
    Inventors: James E. Sheppeck, Jingwu Duan, Chu-Biao Xue, Zelda Wasserman